Johnson & Johnson - McKnight's Long Term Care News

Johnson & Johnson

Clinical briefs for Thursday, July 15

FDA adds provider warning to J&J vaccine regarding rare neurological disorder … Biogen’s dementia drug Aduhelm could cost Medicaid up to $2.2 billion a year … Biden to nominate West Virginia’s Rahul Gupta as drug czar … Antibiotic stewardship lowers outpatient prescribing in VA facilities program … Skip azithromycin as treatment in mild COVID-19, researchers say … HHS provides $398M to small rural hospitals for COVID-19 testing, mitigation

What exactly are we waiting to see? It’s time to act on mandates

As a coalition of long-term care medical and infectious disease experts Tuesday called on healthcare facilities to require COVID-19 vaccines as a condition of employment, I couldn’t help but think of Tom Gorman. I’d seen Tom earlier that morning, outlining his battle with Guillain-Barre syndrome following receipt of Johnson & Johnson’s COVID-19. The avid hiker…

Clinical briefs for Tuesday, July 13

FDA to add warning of rare nerve condition to J&J COVID-19 vaccine … Biden combats drug pricing in executive order; imports from Canada a possibility … Neurologists issue ethical guidance for dementia diagnosis and care … FDA approves drug that slows kidney decline, heart disease in type 2 diabetes … Post-acute COVID-19 patients show poorer health than their cancer rehab peers: study … Prescribing nurses have crucial impact on reducing antibiotic use

Image of gloved hand holding a vial of Johnson & Johnson's investigational COVID-19 vaccine

BREAKING: CDC panel recommends resuming J&J COVID vaccine

The immunization advisory board for the Centers for Disease Control and Prevention has given long-term providers a boost by recommending the resumption of Johnson & Johnson’s COVID-19 vaccine 10 days after officials paused use of the shots to investigate rare blood clots in some recipients.

Next post in News